Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.

Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weiss Bjerrum, Mette Brabrand, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben A Kruse, Hans Torben Mourits-Andersen, Peter Møller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Henriette Skov, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas Stauffer LarsenHans Carl Hasselbalch

Research output: Contribution to journalConference abstract in journalResearchpeer-review

92 Downloads (Pure)
Original languageEnglish
Article numberS131
JournalHemaSphere
Volume2
Issue numberS1
Pages (from-to)18-19
DOIs
Publication statusPublished - 15. Jun 2018
EventEuropean Hematology Association 23rd congress EHA 2018 - Stockholm , Sweden
Duration: 14. Jun 201817. Jun 2018

Conference

ConferenceEuropean Hematology Association 23rd congress EHA 2018
CountrySweden
CityStockholm
Period14/06/201817/06/2018

Cite this

Knudsen, T. A., Lund Hansen, D., Ocias, L. F., Weiss Bjerrum, O., Brabrand, M., El Fassi, D., Frederiksen, M., Kjær, L., Kielsgaard Kristensen, T., Kruse, T. A., Mourits-Andersen, H. T., Møller, P., Overgaard, U. M., Severinsen, M. T., Skov, V. H., Stentoft, J., Starklint, J., de Stricker, K., Thomassen, M., ... Hasselbalch, H. C. (2018). Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients. HemaSphere, 2(S1), 18-19. [S131]. https://doi.org/10.1097/HS9.0000000000000060